These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 8139116

  • 1. [Allogeneic bone marrow transplantation for two patients with acute myeloid leukemia with trilineage myelodysplasia (T-MDS)].
    Fukushima T, Kuriyama K, Yoshida S, Nagai K, Miyazaki Y, Moriuti Y, Tomonaga M.
    Rinsho Ketsueki; 1994 Feb; 35(2):171-6. PubMed ID: 8139116
    [Abstract] [Full Text] [Related]

  • 2. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

  • 3. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.
    Demuynck H, Verhoef GE, Zachee P, Emonds MP, van der Schueren E, van den Berghe H, Vandenberghe P, Casteels-Van Daele M, Boogaerts MA.
    Bone Marrow Transplant; 1996 May; 17(5):745-51. PubMed ID: 8733692
    [Abstract] [Full Text] [Related]

  • 4. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
    Michel G, Leverger G, Leblanc T, Nelken B, Baruchel A, Landman-Parker J, Thuret I, Bergeron C, Bordigoni P, Esperou-Bourdeau H, Perel Y, Vannier JP, Schaison G.
    Bone Marrow Transplant; 1996 Feb; 17(2):191-6. PubMed ID: 8640165
    [Abstract] [Full Text] [Related]

  • 5. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ.
    J Clin Oncol; 2005 Aug 20; 23(24):5675-87. PubMed ID: 16110027
    [Abstract] [Full Text] [Related]

  • 6. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R.
    Exp Hematol; 1995 Dec 20; 23(14):1553-62. PubMed ID: 8542946
    [Abstract] [Full Text] [Related]

  • 7. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
    Gordon BG, Warkentin PI, Strandjord SE, Abromowitch M, Bayever E, Harper JL, Coccia PF.
    Bone Marrow Transplant; 1997 Jul 20; 20(1):5-10. PubMed ID: 9232249
    [Abstract] [Full Text] [Related]

  • 8. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.
    J Clin Oncol; 2008 Feb 01; 26(4):577-84. PubMed ID: 18086801
    [Abstract] [Full Text] [Related]

  • 9. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
    Ortega JJ, Díaz de Heredia C, Olivé T, Bastida P, Llort A, Armadans L, Torrabadella M, Massuet L.
    Haematologica; 2003 Mar 01; 88(3):290-9. PubMed ID: 12651268
    [Abstract] [Full Text] [Related]

  • 10. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia.
    Ballen KK, Gilliland DG, Guinan EC, Hsieh CC, Parsons SK, Rimm IJ, Ferrara JL, Bierer BE, Weinstein HJ, Antin JH.
    Bone Marrow Transplant; 1997 Nov 01; 20(9):737-43. PubMed ID: 9384475
    [Abstract] [Full Text] [Related]

  • 11. Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies.
    Malladi RK, Peniket AJ, Norton AE, Campbell AJ, Collins GP, Samol J, Eagleton H, Miller E, Morgenstern G, Jones J, Keen-Mcguire A, Barnardo M, Littlewood TJ.
    Eur J Haematol; 2004 Aug 01; 73(2):85-92. PubMed ID: 15245506
    [Abstract] [Full Text] [Related]

  • 12. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Ball E, Cook D, Andresen S, Kuczkowski E, Bolwell B.
    Bone Marrow Transplant; 2005 Feb 01; 35(3):247-52. PubMed ID: 15580282
    [Abstract] [Full Text] [Related]

  • 13. Donor leukocyte infusions for treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation.
    Forés R, Díez-Martin JL, Briz M, Cabrera JR, Sanjuán I, Regidor C, Garcia-Talavera J, Fernandez MN.
    Bone Marrow Transplant; 1996 Mar 01; 17(3):439-41. PubMed ID: 8704703
    [Abstract] [Full Text] [Related]

  • 14. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
    Frassoni F, Labopin M, Gluckman E, Prentice HG, Vernant JP, Zwaan F, Granena A, Gahrton G, De Witte T, Gratwohl A, Reiffers J, Gorin NC.
    Bone Marrow Transplant; 1996 Jan 01; 17(1):13-8. PubMed ID: 8673048
    [Abstract] [Full Text] [Related]

  • 15. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J.
    Bone Marrow Transplant; 1996 May 01; 17(5):685-9. PubMed ID: 8733682
    [Abstract] [Full Text] [Related]

  • 16. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
    Ogasawara T, Yasuyama M, Kawauchi K.
    Am J Hematol; 2005 Jun 01; 79(2):136-41. PubMed ID: 15929101
    [Abstract] [Full Text] [Related]

  • 17. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
    Worth L, Tran H, Petropoulos D, Culbert S, Mullen C, Roberts W, Przepiorka D, Chan K.
    Bone Marrow Transplant; 1999 Nov 01; 24(9):947-52. PubMed ID: 10556952
    [Abstract] [Full Text] [Related]

  • 18. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Runde V, de Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A, Niederwieser D, Labopin M, Walter-Noel MP, Bacigalupo A, Jacobsen N, Ljungman P, Carreras E, Kolb HJ, Aul C, Apperley J.
    Bone Marrow Transplant; 1998 Feb 01; 21(3):255-61. PubMed ID: 9489648
    [Abstract] [Full Text] [Related]

  • 19. [Second marrow transplantation following high dose busulfan, etoposide, and Ara-C after testicular relapse in a patient with AML].
    Matsue K, Tohi T, Masauji N, Tsukuda K.
    Rinsho Ketsueki; 1992 Mar 01; 33(3):338-42. PubMed ID: 1578638
    [Abstract] [Full Text] [Related]

  • 20. [Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group].
    Hübner G, Link H, Schönrock-Nabulsi P, Wandt H, Gramatzki M, Löffler B, Fackler-Schwalbe I, Queisser W, Brack N, Geer T, Raab M, Ohl S, Schneider B, Schneider C, Freund M, Poliwoda H, Ehninger G.
    Med Klin (Munich); 1996 Apr 12; 91 Suppl 3():26-32. PubMed ID: 8692115
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.